- Home
- GLNG vs LQDA Comparison
GLNG vs LQDA Comparison
Compare GLNG & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLNG | LQDA |
|---|---|---|
| Founded | 1946 | 2004 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.1B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GLNG | LQDA |
|---|---|---|
| Price | $37.07 | $34.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $51.13 | $37.40 |
| AVG Volume (30 Days) | 1.1M | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ 333.77 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $326,627,000.00 | $69,216,000.00 |
| Revenue This Year | $50.18 | $994.17 |
| Revenue Next Year | $0.91 | $169.25 |
| P/E Ratio | $67.01 | ★ N/A |
| Revenue Growth | 19.15 | ★ 343.41 |
| 52 Week Low | $29.56 | $11.26 |
| 52 Week High | $45.98 | $36.41 |
Technical Indicators
Market Signals| Indicator | GLNG | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 57.54 |
| Support Level | $36.75 | $33.45 |
| Resistance Level | $38.39 | $36.60 |
| Average True Range (ATR) | 0.80 | 1.48 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 21.96 | 57.46 |
Price Performance
Historical ComparisonAbout GLNG Golar Lng Ltd
Golar LNG Ltd is a midstream LNG company that operates in the transportation, regasification, liquefaction, and trading of LNG. The segment in which the group operates includes Shipping, FLNG (Floating Liquefaction Natural Gas vessels), and Corporate and other. It generates maximum revenue from the FLNG segment.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.